High-throughput sequencing (HTS) has revolutionized genetics by enabling the detection of sequence variants at hitherto unprecedented large scale. Despite these advances, however, there are still remaining challenges in the complete coverage of targeted regions (genes, exome or genome) as well as in HTS data analysis and interpretation. Moreover, it is easy to get overwhelmed by the plethora of available methods and tools for HTS. Here, we review the step-bystep process from the generation of sequence data to molecular diagnosis of Mendelian diseases. Highlighting advantages and limitations, this review addresses the current state of (1) HTS technologies, considering targeted, whole-exome, and whole-genome sequencing on short-and long-read platforms; (2) read alignment, variant calling and interpretation; as well as (3) regulatory issues related to genetic counseling, reimbursement, and data storage. 
counseling, reimbursement, and data storage. A glossary including abbreviations is provided (Table 1) .
| HIGH-THROUGHPUT SEQUENCING TECHNOLOGIES

| Targeted sequencing
Genes of interest, so-called gene panels, can be enriched and sequenced simultaneously by TS, which serves as an inexpensive and rapid first-tier test with compatibility to benchtop short-read sequencers (eg, Illumina MiSeq/NextSeq and Thermo Fisher Scientific Ion PGM/Proton) and with especially high read depth of targeted regions (Table 2) . Consequently, TS enables sequence variant detection in samples with very low non-reference allele frequencies caused by germline mosaics or clonal complexity of tumors. 3, 4 Moreover, the use of disease-related gene panels facilitates the interpretation of detected sequence variants and minimizes the chance of incidental findings. 5 According to the guidelines and recommendations of the American College of Medical Genetics and Genomics (ACMG), only genes with a scientifically sufficiently supported role in disease should be included in a clinical gene panel. 6 Limitations of TS include the difficulty of detecting clinically relevant sequence variants, especially CNVs, in regions with an insufficient number of reads (ie, below the limit of variant calling) resulting in discontinuous coverage (<100%) ( Table 2 ). Incomplete coverage can result from poor enrichment of GC-rich regions such as first exons and from the absence of probes used for enrichment ( Figure 2 ). 7 Furthermore, due to the identification of novel genedisease associations, gene panels require updates, especially in diseases with incompletely understood molecular basis. Thus, TS may be inconclusive in the case of negative results, providing no diagnosis and requiring a different gene panel or an additional method for CNV detection, or second-tier sequencing (WES and/or WGS). Updating gene panels can be avoided by sequencing all (known) genes (~25 000) applying WES or WGS.
| Whole-exome sequencing
As the exome encompasses~2% of the human genome but harbors 85% of all described disease-causing sequence variants, 8, 9 WES aims to sequence the coding exons of all our known genes, that is, considerably more than TS. The so-called clinical exome encompasses 5000 disease-associated genes (eg, Agilent SureSelect Focused
Exome, Illumina TruSight One and Roche NimbleGen SeqCap EZ
High-throughput sequencing (Panel, WES, WGS)
Selection of the appropriate technique based on amount and quality of material, required read depth, read length, error rate, turnaround time
Alignment and variant calling
Depending on hardware/software, sequence variant type, and version of reference sequence differences exist regarding accuracy, runtime, disk footprint, data storage (and safety)
Variant filtering and interpretation
Challenges regarding VUS, especially intronic, intergenic and splicing variants, and due to potential monoallelic expression 
Consequence of variant known?
Problem: function for ~50% of genes not known Benchmark reference materials: samples with known and validated sequence variants, which can be used for the benchmarking and evaluation of sequencing platforms and software tools.
Molecular diagnosis including genetic counseling yes no
Bioinformatic pipelines: workflow combining a variety of software tools for biological data analysis.
Clinical exome: HTS restricting sequencing to disease-associated genes.
ClinVar: a freely accessible, public archive for the clinical interpretation of human sequence variants (ncbi.nlm.nih.gov/clinvar).
CNV: copy number variation (deletions and duplications >50 bp).
CRISPR-Cas9-targeted enrichment: a novel, amplification-free enrichment technique that employs the CRISPR-Cas9 system for specific targeting of multiple genomic loci. 105 De novo assembly for CNV detection: approach to identify SVs by merging and ordering unaligned reads to reassemble the original sequence from which the reads were sampled.
Disk footprint: storage footprint on a disk expressed in bytes such as mega-(MB), giga-(GB) or terabytes (TB).
Enrichment bias: in HTS with a hybridization-based capture and/or amplification step, certain genomic regions are enriched with different efficiency (eg, due to differences in GC content). Indeed, GC-rich regions are difficult to enrich, leading to a below-average number of reads and to incomplete coverage of targeted regions (genes, exome or genome). GC-rich regions: genomic regions containing high numbers of guanine (G) and cytosine (C). Due to the base stacking, GC-rich genomic regions are particularly stable and hence more difficult to enrich.
HGMD: the commercial Human Gene Mutation Database constitutes a comprehensive core collection of data on germline sequence variants in nuclear genes underlying or associated with human inherited disease (portal.biobase-international.com). The less up-to-date public version of HGMD is freely available for academic institutions/non-profit organizations (www.hgmd.cf.ac.uk).
HPO: the Human Phenotype Ontology is a database aiming to provide a standardized vocabulary of phenotypic abnormalities encountered in human disease (human-phenotype-ontology.github.io).
HTS: high-throughput (formerly next-generation) sequencing.
Incidental findings: sequence variants with potential health or reproductive importance but unrelated to the clinical phenotype for which sequencing was performed.
Indels: small insertions and deletions (≤50 bp).
Interpretation databases: Examples for SNVs/indels: OMIM, HGMD, ClinVar, LSDB, ExAC/gnomAD; for CNVs: DGV (dgv.tcag.ca). LRS: long-read sequencing.
LSDB: locus specific mutation database (hgvs.org/locus-specific-mutation-databases).
Mappability: computed value giving the inverse of the number of times that a read maps to the genome for a given read length and number of allowed mismatches (eg, m = 2). A mappability of 1 indicates unambiguous mappable regions, whereas a mappability <1 indicates regions which tend to produce ambiguous mappings.
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Non-reference allele: allele with sequence variant, that is, with sequence differing from the reference genome.
OMIM: Online Mendelian Inheritance in Man is a freely available, comprehensive, authoritative compendium of human genes and genetic phenotypes, containing information on all known Mendelian disorders and currently over 15 000 genes (omim.org).
ONT: Oxford Nanopore Technologies (nanoporetech.com).
PacBio: Pacific Biosciences (pacb.com).
Paired-end mapping: approach to identify SVs by evaluating the span and orientation of paired-end reads. CNVs are indicated by read pairs with mapping spans inconsistent with the expected insert size.
Precision: analysis quality measure (TP/[TP + FP]), analogous to positive predictive value.
Random monoallelic expression (MAE): only 1 of 2 alleles of a gene is actively transcribed, while the other allele is silent. MAE can occur in a random fashion, varying in an interindividual-, tissue-and/or cell-type-specific manner 87 and its evaluation is assisted by the database of monoallelic expression (dbMAE, mae.hms.harvard.edu), containing information on tissue-specific expression patterns of autosomal genes. 88 Read alignment: mapping/assigning of raw short or long reads (sequencer output stored in FASTQ or related formats) to the reference genome.
Software examples for the alignment of short reads: BWA-MEM, 63 Isaac, 65 GENALICE MAP (genalice.com).
60
Read depth: number of aligned sequencing reads covering a specific genomic position.
(Continues) MedExome), thereby covering only~20% of the entire exome and thus requiring additional analyses if the disease-causing sequence variant remains undetected. 10, 11 In contrast, WES not only covers exons of already disease-associated genes but also allows for the identification of novel gene-disease associations in diseases with yet unknown molecular basis in a cost-effective way. 12, 13 It is therefore not surprising that WES is widely used and has been advocated as a first-tier test instead of TS. 14, 15 The cost efficiency of WES makes trio analysis feasible (ie, sequencing the patient and his/her parents), which facilitates data interpretation and increases the diagnostic yield considerably (from~20% to~30%). 16, 17 WES data analysis can be limited in silico to a gene panel (genes of interest) and subsequently expanded if necessary, thereby reducing the potential for the discovery of incidental/secondary findings. 18, 19 Although WES can detect more sequence variants than TS, WES has similar limitations as TS ( Figure 2 , Table 2 ). Accordingly, WES may fail to cover poorly enriched parts of the exome and hence to detect clinically relevant sequence variants, that is,~400 exonic disease-causing variants listed in HGMD (portal.biobase-international.
com). 7 The incomplete coverage of WES may be improved by combining enrichment kits (eg, Agilent SureSelect, Illumina TruSeq Capture, and Roche NimbleGen SeqCap EZ) or by using a high concentration of capture probes that cover difficult-to-enrich regions. ; (2) to detect non-exonic sequence variants 7, 21 and (3) to improve CNV detection, 7, 24 leading to increased diagnostic yield over WES. [25] [26] [27] [28] WGS data interpretation, as in WES, may initially focus on a region of interest by applying in silico gene panels. To date, deep intronic, intergenic, and regulatory sequence variants are difficult or impossible to interpret at the DNA level only. 29 However, even such sequence variants can be of importance in the near or distant future, adding a superior value to WGS data and putting the higher costs of WGS into a lifetime perspective. This superior value of WGS can be recognized in the emerging field of pharmacogenetics. 30 Pharmacogenetic predisposition, which can be obtained by subsequent filtering of appropriate HTS data, is clinically highly relevant, because it can play a pivotal role in the success or failure of a pharmacological therapy. Notably, some pharmacogenetically-relevant sequence variants, such as a single nucleotide polymorphism (SNP) in the promoter region of VKORC1
(rs9923231) causing low-warfarin-dose phenotype 31 or structural variations (SVs) affecting drug targets, 32 can readily be detected by WGS but not by WES. The limitation of WGS is mainly Read-depth analysis: approach to identify CNVs by comparing the read depth of genomic regions in a sample to its own average read depth or to the read depth of the same region in one or multiple control samples.
Reference genome: the current human reference genome (assembly of a number of donors) is GRCh38 (the Genome Reference Consortium human genome build 38) or hg38 (equivalent version). Reference genomes are improved by the Genome Reference Consortium and these improvements should lead to more accurate genomic analyses. 106 The previous human reference genome GRCh37/hg19 is still widely used.
RefSeq: the Reference Sequence collection (ncbi.nlm.nih.gov/refseq) provides a comprehensive, non-redundant, well-annotated set of sequences, including genomic DNA, transcripts, and proteins. RefSeq sequences form a foundation for medical, functional, and diversity studies.
SAM (sequence alignment map): file format for storing biological sequences aligned to the reference genome. It is widely used for storing data, such as nucleotide sequences. The format supports short and long reads.
Sensitivity/recall: analysis quality measure (TP/[TP + FN]), analogous to true positive rate or probability of detection.
SNP (single-nucleotide polymorphism): variation in a nucleotide at a single specific position among individuals, occurring with appreciable relative frequency (e.g. >1%) within a population (not to be confused with SNV).
SNV (single-nucleotide variant): variation in a nucleotide at a single specific position between individual and reference genomes without any frequency limitation (not to be confused with SNP). dbscSNV is a database for SNVs within splicing consensus regions. 82 Split reads: approach to identify SVs by investigating breakpoints in reads split into two parts and aligned separately to the genome (different position and/or orientation).
SRS: short-read sequencing.
SRS dead zone: genomic region for which multiple matches of short-read sequencing reads exist, making unambiguous mapping impossible.
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STR (short tandem repeat): DNA sequence with a DNA motif of a few base pairs repeated in tandem (also known as microsatellite).
SV (structural variation): sequence variant affecting the structure of a chromosome (eg, copy number variations, insertions, and translocations).
TP (true-positive sequence variant): sequence variant which are present and detected by variant calling.
Trio analysis: HTS data of an index case and his/her parents is used to facilitate the detection of disease-causing sequence variant(s).
TS (targeted sequencing): a rapid and cost-effective way to detect known and novel variants in selected/enriched sets of genes or genomic regions (specified in gene panels).
Variant calling: process of identifying sequence variants by detecting positions differing between sample sequence and reference genome. Software examples for SNVs/Indels: GATK-HC, 64 Isaac, 65 or GENALICE MAP (genalice.com); for CNVs: CNVnator, 69 BreakDancer, 70 LUMPY, 71 Manta, 72 Cortex 73 ; for STRs: lobSTR, 77 ExpansionHunter, 78 HipSTR, 79 or STRetch. VUS: sequence variants of unknown significance.
WES: whole-exome sequencing.
WGS: whole-genome sequencing. Abbreviations: ONT, Oxford Nanopore Technologies; PacBio, Pacific Biosciences; PCR, polymerase chain reaction; SV, structural variation; TS, targeted sequencing; WES, whole-exome sequencing; WGS, wholegenome sequencing.
a Parameters of short-read sequencing are adapted to Illumina MiSeq v3 system (TS) and Illumina HiSeq X Ten system (WES, WGS). Note that reads cannot be unambiguously aligned to repetitive/homologous regions larger than the read length, that is, mappability <1 (cf. Figure 3) .
b
Maximal read length only limited by length of the fragments sequenced (template).
c
Costs calculated according to most frequently used sequencing systems, library preparation kits, and reagents for the respective application, considering "typical read depth."
d According to nanoporetech.com/about-us/news/human-genome-minion.
e Calculated for files like FASTQ, BAM, and VCF using corresponding in-house and publicly available data (github.com/nanopore-wgs-consortium/NA12878, ftp-trace.ncbi.nih.gov/giab/ftp/data/AshkenazimTrio). As file sizes can vary substantially according to the sequencing platform, read depth, and analysis software used, [57] [58] [59] [60] storage footprint (in GB) is estimated/exemplified for typical cases. Costs were calculated as described elsewhere, 107 considering disk footprint for backup as well. For TS, disk footprint was calculated for 100 average-sized genes with 2.5-kb coding region per gene.
f According to illumina.com/documents/products/datasheets/datasheet-hiseq-x-ten.pdf.
g According to allseq.com/knowledge-bank/sequencing-platforms/pacific-biosciences.
determined by the sequencing read length leading to uncertain (<1) mappability (Table 2 ).
| Short-read sequencing
TS, WES, and WGS have traditionally been performed using shortread sequencing (SRS), also known as second-generation sequencing.
SRS typically produces reads that are 100 to 400 bp in length, depending on the used technology. 
FIGURE 2 Coverage difference between WES and WGS exemplified for 2 genes (adapted and modified from Reference 7). (A) Not all exons are captured leading to low/insufficient read depth in WES in contrast to WGS. (B) GC-rich (77%) exon 2 of KLF2 is completely covered by PCR-free WGS and almost completely by WGS with PCR, while a large gap in coverage is present in WES. Coverage tracks are visualized by the Integrative
Genomics Viewer (IGV, broadinstitute.org/igv). For abbreviations, see Figure 1 and Table 2 . *Designed target region of Agilent SureSelect v5 + UTR all SRS platforms is the short read length, leading to read alignment difficulties ( Figure 3) . Indeed, bioinformatic alignment of reads matching to more than 1 genomic location due to sequence homology (mappability <1) is ambiguous and can lead to misalignments as well as to false-positive and false-negative variant calling. [33] [34] [35] To increase the awareness of SRS limitations, we filtered all 
| Long-read sequencing
The read and mappability limitations of SRS can be overcome by using LRS. LRS with multi-kb-long reads facilitates unambiguous alignment to a reference genome due to the increased ability of long reads to completely span large complex, repetitive or homologous regions ( Figure 3) . By using LRS, the unambiguously mappable region of the genome can therefore be increased, minimizing clinically relevant false-negative results. 37 SVs, discovery of transcriptome complexity and novel isoforms, and detection of methylation status. [37] [38] [39] [40] The latest PacBio sequencer (Sequel) has been introduced to increase throughput and cost effectiveness but both remain considerably lower than in SRS.
The PacBio competitor ONT exploits the voltage change difference among nucleotides passing through a biological nanopore. ONT reads are on average 7 to 8 kb long 41 and can be generated on devices of different sizes such as the portable mobile-phone-sized PacBio and ONT both have high raw read error rates of~10%. 38, 41 As such errors are distributed randomly, their effect on consensus sequence and variant calling, however, can be minimized by increasing read depth and reading a template molecule multiple times (PacBio) or twice (ONT). 49 On the horizon are other real LRS plat- Although synthetic LRS may miss regions detectable by real LRS, it is predictable that LRS, synthetic or real, will soon find broad applications in clinical genetics.
| READ ALIGNMENT AND VARIANT CALLING
To detect sequence variants, the HTS output (short or long reads), stored in FASTQ or related formats, requires unambiguous read alignment to the reference genome (generating SAM/BAM files) and accurate variant calling (stored in (g)VCF files) using appropriate bioinformatic pipelines. As bioinformatic tools are typically specialized in a certain step of data analysis or have different performance, 55,56 a combination of appropriate tools is recommended to detect different types of sequence variants and to minimize clinically relevant falsenegative results (ie, to zero as missing the disease-causing sequence variant leads to missing the molecular diagnosis). While the performance of HTS platforms has frequently been addressed in the last years, the performance of bioinformatic tools, especially for variant interpretation and LRS data analysis, is still a matter of ongoing research involving benchmark reference materials.
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| SNVs and insertions/deletions
The current de facto standard for the alignment of short reads and the calling of SNVs and indels is the BWA/GATK best practices pipeline, 62 which combines the read aligner BWA-MEM 63 and the variant caller GATK-HC. 64 As the computation time (~93 hours) and disk footprint (~254 GB) of BWA/GATK (version 3.5) is less suitable for large WGS data sets (60×), alternative tools such as Illumina's Isaac 65 and GENALICE MAP (genalice.com) have been introduced, offering faster analyses with reduced output file sizes. 60 Indeed, in our benchmarking study, GENALICE MAP showed ultrarapid speed (~1 hour) and superior low disk footprint (~6 GB) with BWA/GATKlike sensitivity for 60× short-read WGS data. 60 However, the run time of BWA/GATK may be accelerated 5× by the upcoming GATK version 4.0 and/or the DRAGEN platform (edicogenome.com) or compressive methods such as CORA, 66 allowing current BWA/GATK users to move on from TS or WES to WGS data analyses.
| Copy number variations
CNVs and copy neutral rearrangements such as inversions and translocations are SVs affecting large genomic segments. 67 Except for the software GROM (Genome Rearrangement OmniMapper), a recently introduced all-in-one solution to detect SNVs, indels, CNVs, and other SVs, 68 algorithms used for calling of SNVs and indels are not suited for the detection of larger sequence variants, requiring dedicated algorithms for CNV detection. Calling of CNVs from HTS data can be achieved by different approaches such as read-depth analysis, paired-end mapping, split reads, and de novo assembly. 24 A wide variety of CNV-calling tools uses 1 or several of these strategies, for example, CNVnator (read depth), 69 BreakDancer (paired-end mapping), 70 LUMPY and Manta (paired-end mapping and split reads), 71, 72 or Cortex (de novo assembly). 73 Except for read-depthbased tools, CNV calling strategies are only applicable for WGS data, enabling the detection not only of CNVs but also of copy neutral SVs at base-pair resolution. 74 For CNV detection in TS and WES data, dedicated tools have been developed, 75 taking the enrichment bias into account, however, without achieving the accuracy observed in WGS data. 24, 76 As CNV calling tools differ in their performance and hence users need to combine multiple algorithms, no de facto standard has been established for CNV detection.
| Short tandem repeats
STR expansions are highly relevant in clinical genetics but difficult to genotype accurately by SRS due to low-quality calls, very high GC content (as in fragile X syndrome) and/or expansions longer than the read length leading to ambiguous alignments that can be overcome by LRS. A number of software tools attempting to overcome SRS challenges for STR genotyping have recently been introduced, such as lobSTR, 77 ExpansionHunter, 78 HipSTR, 79 and STRetch, 80 demonstrating that also SRS data can lead to useful STR profiles. While the interpretation of STR expansions with known disease association is straightforward, the variant filtering and interpretation of other sequence variant types can be challenging.
| VARIANT FILTERING AND INTERPRETATION
HTS outputs about one called variant per 1000 bp of sequenced genome compared to the reference genome, leading to ten thousands and millions of sequence variants in WES and WGS, respectively. For time-consuming manual evaluation, appropriate filtering can help to reduce these large numbers by distinguishing pathogenic sequence variants from (likely) benign ones ( Figure 1) . 81 In silico gene panels can restrict sequence variants to the genes of interest. Gene-disease
and variant-disease associations may be found in the literature (ncbi.
nlm.nih.gov/pubmed) and databases such as OMIM (omim.org), HGMD (portal.biobase-international.com), ClinVar (ncbi.nlm.nih.gov/ clinvar), and LSDB (hgvs.org/locus-specific-mutation-databases).
SNVs and indels can be prioritized based on their population fre- Table 1 ). 85 Intergenic CNVs disrupting the boundaries of topologically associating domains (TADs), in which genes have a higher probability of physical interaction, 86 should be included into a comprehensive CNV interpretation. In the interpretation of pathogenicity (especially in segregation analyses and genetic counseling), disease onset, parental mosaicism, dual molecular diagnoses (modifier), and random autosomal monoallelic expression 87, 88 (Table 1) should also be considered.
Moreover, although the accurate prediction of splicing defect is currently challenging and needs the development of better in silico tools in the future, it is clinically relevant to consider the possibility of aberrant splicing for any intronic and exonic sequence variants detected in diseases. [89] [90] [91] [92] [93] [94] As a considerable number of new genedisease and variant-disease associations have been reported annually, the regular reevaluation of HTS data using current knowledge is indicated for unsolved cases with suspected Mendelian disorder. Nevertheless, despite the most comprehensive interpretation, variants of unknown significance (VUS) will remain one of the most frequent entities for years in the current genomics era. 81 Sequence variants to be reported might be confirmed by The reimbursement for clinical genetic testing varies among countries. Even when ordered by a qualified person (eg, medical geneticist, primary care doctor) it is recommended to inquire of the insurance company beforehand if costs are covered (ghr.nlm.nih.gov/ primer/testing/insurancecoverage). Furthermore, when it comes to insurances there is a risk for genetic discrimination, which needs to be prevented. 96 Regulations are required in a way that both, patients and the healthcare systems, can benefit from the scientific advances. 97 The goal should be toward the benefit of patients in need while still being economically feasible.
With ever-increasing amounts of genetic data there are emerging regulatory issues regarding data safety and storage. Although cloud environments enable high-capacity data storage (eg, Amazon Web Services, aws.amazon.com), there are legitimate concerns about the privacy and security of sensitive cloud-stored genetic data, 98 indicating the need for more secure and decentralized solutions (eg, UnLynx). 99 Data sharing, which facilitates genotype-phenotype correlation, is subject to further discussions as it has been shown that even after de-identification, re-identification of a single person is at least partially possible by either STR 100 or SNP genotyping. 101 
| CONCLUSIONS AND PERSPECTIVES
The workflow used in HTS impacts the diagnostic yield. Contrary to expectations, whole does not equal whole in short-read WES and WGS. From a technical point of view, PCR-free WGS is not only the most comprehensive SRS method but also the better WES as it provides the most uniform/complete coverage of the genome and covers the exome better than WES. 7 As a considerable number of coding exons remain insufficiently covered by SRS, LRS is envisioned as the future of sequencing. Until then, however, LRS could complement SRS by sequencing of insufficiently covered regions, for the selection of which CRISPR-Cas9-targeted enrichment could be considered. 105 In addition to LRS, next-generation genome mapping on nanochannel arrays (bionanogenomics.com) may enter clinical genetics enabling the detection of large SVs. 102 In the next years, the detection of CNVs and STR expansions by appropriate HTS methods as well as the combination of DNA and transcriptome sequencing will increase the diagnostic yield. 103 Fueled by technological advances, HTS has led to the current situation in which our ability to sequence is greater than our ability to interpret the detected sequence variants. Indeed, the effects of VUS and non-exonic sequence variants pose a challenge for variant interpretation. Methods used for alignment, variant calling, and filtering can considerably influence sequence variant detection. Thus, it is recommended to use more than 1 independent data analysis pipeline and to reevaluate unsolved cases to minimize clinically relevant falsenegative results. Exclusively relying on in silico interpretation tools is dangerous, because, although powerful, they are not without fault and not a replacement for expert review and functional analyses. 104 HTS for clinical applications has not yet reached its full potential, because of remaining technical (hardware and software) and regulatory issues. Especially an appropriate solution will have to be found for data storage and safety because of ever-increasing amounts of genomic data with lifetime value.
